Abbott anticipates incurring tariff expenses amounting to "a few hundred million" in 2025.

Abbott reported a Q1 revenue of $10.36 billion, marking a 4% year-over-year increase, with medical device sales reaching $4.9 billion (up 9.9%) and net earnings of $1.33 billion (up 8.2%). CEO Robert Ford indicated that the company anticipates a "few hundred million dollars" impact from tariffs but remains committed to its earnings forecast for 2025. Abbott is expanding manufacturing in Illinois and Texas and is strategizing for long-term tariff implications, recognizing that tariffs tend to persist. The company is also seeking tariff exemptions for its medical devices.